- Trials with a EudraCT protocol (20)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (22)
20 result(s) found for: Brainstem glioma.
Displaying page 1 of 1.
| EudraCT Number: 2016-000758-37 | Sponsor Protocol Number: NO18517 | Start Date*: 2016-08-23 | ||||||||||||||||
| Sponsor Name:F. Hoffmann-La Roche AG | ||||||||||||||||||
| Full Title: A Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas | ||||||||||||||||||
| Medical condition: High Grade Glioma Brainstem Glioma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: Outside EU/EEA | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2007-001768-60 | Sponsor Protocol Number: CNS 2007 04 | Start Date*: 2007-10-01 | |||||||||||
| Sponsor Name:University of Birmingham | |||||||||||||
| Full Title: A Phase II Multi-Centre Study of Concomitant and Prolonged Adjuvant Temozolomide with Radiotherapy in Diffuse Pontine Gliomas | |||||||||||||
| Medical condition: Diffuse pontine glioma in children | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-003362-84 | Sponsor Protocol Number: FSJD-DIPG-DC | Start Date*: 2016-05-18 | |||||||||||
| Sponsor Name:Fundació Sant Joan de Déu | |||||||||||||
| Full Title: Phase Ib clinical trial on the safety of immunotherapy with autologous dendritic cells primed with lysate allogeneic tumor lines in patients with diffuse intrinsic pontine glioma ( DIPG ) | |||||||||||||
| Medical condition: Diffuse intrinsic pontine glioma (DIPG) | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-002185-23 | Sponsor Protocol Number: DIPG | Start Date*: 2015-07-29 | |||||||||||
| Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
| Full Title: Phase 2 open label randomized study of radiotherapy, concomitant nimotuzumab and vinorelbine and re-irradiation at relapse versus radiotherapy and multiple elective radiotherapy courses with concom... | |||||||||||||
| Medical condition: diffuse intrinsic pontine glioma | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-001045-12 | Sponsor Protocol Number: NO21125 | Start Date*: 2016-07-20 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche AG | |||||||||||||
| Full Title: A Phase II Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas. | |||||||||||||
| Medical condition: Intrinsic Brainstem Glioma | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-000636-40 | Sponsor Protocol Number: PNOC022 | Start Date*: 2022-10-20 | |||||||||||||||||||||
| Sponsor Name:Pacific Pediatric Neuro-Oncology Consortium (PNOC) | |||||||||||||||||||||||
| Full Title: PNOC022: A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initi... | |||||||||||||||||||||||
| Medical condition: Diffuse Midline Gliomas, H3K27M mutant | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: NL (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2018-002654-79 | Sponsor Protocol Number: P160954J | Start Date*: 2019-02-13 | |||||||||||
| Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
| Full Title: TEMOTRAD 01 : First-line chemotherapy with temozolomide alone for non-enhancing adult brainstem gliomas, with a diffuse subtype and showing clinical and/or radiological infiltrative pattern of pro... | |||||||||||||
| Medical condition: adult brainstem gliomas | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-004125-23 | Sponsor Protocol Number: CCRG19-002 | Start Date*: 2021-05-10 | |||||||||||||||||||||
| Sponsor Name:Antwerp University Hospital | |||||||||||||||||||||||
| Full Title: Adjuvant dendritic cell immunotherapy complementing conventional therapy for pediatric patients with high-grade glioma and diffuse intrinsic pontine glioma | |||||||||||||||||||||||
| Medical condition: Childhood high-grade glioma and diffuse intrinsic pontine glioma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: BE (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2009-016870-33 | Sponsor Protocol Number: CILENT-0902 | Start Date*: 2010-05-20 | |||||||||||
| Sponsor Name:Centre Oscar Lambret | |||||||||||||
| Full Title: Cilengitide (EMD121974) in combination with irradiation in children and young adults with newly diagnosed diffuse intrinsic pontine glioma : Phase I study | |||||||||||||
| Medical condition: Newly diagnosed diffuse intrinsic pontine glioma | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-016080-11 | Sponsor Protocol Number: DIPGstudyVUmc01 | Start Date*: 2011-02-25 | |||||||||||
| Sponsor Name:VU University Medical Center | |||||||||||||
| Full Title: A COMPREHENSIVE AND TARGETED THERAPY APPROACH IN PEDIATRIC MALIGNANT PONTINE GLIOMAS | |||||||||||||
| Medical condition: Pediatric malignant pontine gliomas | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-001929-32 | Sponsor Protocol Number: 2014/2126 | Start Date*: 2014-08-25 | |||||||||||
| Sponsor Name:Gustave Roussy | |||||||||||||
| Full Title: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication | |||||||||||||
| Medical condition: Diffuse Intrinsic Pontine Glioma | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Prematurely Ended) ES (Temporarily Halted) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-000095-28 | Sponsor Protocol Number: H3E-MC-JMHW | Start Date*: 2017-03-02 |
| Sponsor Name:Eli Lilly and Company | ||
| Full Title: A Phase II Study of Pemetrexed in Children with Recurrent Malignancies | ||
| Medical condition: Recurrent Malignancies (recurrent solid tumors): Target tumor types were osteosarcoma, Ewing sarcoma/peripheral PNET, rhabdomyosarcoma, neuroblastoma (measurable disease), neuroblastoma (metaiodob... | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2013-004187-56 | Sponsor Protocol Number: HIT-HGG-2013 | Start Date*: 2017-04-24 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Georg-August-Universität Göttingen, Stiftung Öffentlichen Rechts, Universitätsmedizin Göttingen | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: International cooperative Phase III trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents < ... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: First-line therapy of newly diagnosed, previously untreated high grade glioma, diffuse pontine glioma, and gliomatosis cerebri in children and adolescents <18 years. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) AT (Completed) NL (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2007-000128-42 | Sponsor Protocol Number: HIT-HGG-2007 | Start Date*: 2009-03-19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Martin-Luther-University Halle-Wittenberg | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: International cooperative Phase II trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children ≥ 3 years and adole... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: 1st line therapy of newly diagnosed, previously untreated high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents ≥ 3 years and < 18 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) AT (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2009-011898-33 | Sponsor Protocol Number: HIT-HGG-CilMetro | Start Date*: 2011-11-28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Martin-Luther-Universität Halle-Wittenberg | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Treatment of relapsed or refractory high grade gliomas and diffuse intrinsic pontine gliomas in paediatric patients ≥ 3 years and < 18 years of age. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2018-002688-24 | Sponsor Protocol Number: 2018/2797 | Start Date*: 2019-04-11 | ||||||||||||||||
| Sponsor Name:Gustave Roussy | ||||||||||||||||||
| Full Title: Phase I-II study of nivolumab in combination with temozolomide and radiotherapy in children and adolescents with newly diagnosed high-grade glioma | ||||||||||||||||||
| Medical condition: Newly diagnosed High-Grade Gliomas (HGG) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2010-019348-37 | Sponsor Protocol Number: CLDE225X2104 | Start Date*: Information not available in EudraCT | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||||||||||||||||||||||
| Full Title: A phase 1 study of LDE225 in pediatric patients with recurrent or refractory medulloblastoma or other tumors potentially dependent on the Hedgehog-signaling pathway | ||||||||||||||||||||||||||||||||||||||
| Medical condition: pediatric patients with recurrent or refractory medulloblastoma or other tumors potentially dependent on the Hedgehog-signaling pathway (rhabdomyosarcoma, neuroblastoma, hepatoblastoma, high-grade ... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Completed) GB (Completed) IT (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2014-005190-36 | Sponsor Protocol Number: 20050252 | Start Date*: 2015-01-22 | ||||||||||||||||||||||||||
| Sponsor Name:Amgen Inc | ||||||||||||||||||||||||||||
| Full Title: A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children with Solid Tumors | ||||||||||||||||||||||||||||
| Medical condition: Solid Tumours | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2022-002720-12 | Sponsor Protocol Number: GDX-44-016 | Start Date*: 2023-03-20 | |||||||||||
| Sponsor Name:Guerbet | |||||||||||||
| Full Title: Performance of Elucirem® (gadopiclenol) in Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) perfusion of brain gliomas | |||||||||||||
| Medical condition: Naive or recurrent primary glial tumor | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-000729-55 | Sponsor Protocol Number: 8669-056 | Start Date*: 2011-12-15 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
| Full Title: A Phase I Study of Ridaforolimus in Paediatric Patients with Advanced Solid Tumours | |||||||||||||
| Medical condition: advanced solid tumours including lymphoma and tumours of the central nervous system | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) FR (Completed) Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
